| Literature DB >> 35511325 |
Ju-Hyung Lee1, Joo-Hong Park2.
Abstract
Growing evidence suggests that the gut microbiome is an important contributor to metabolic diseases. Alterations in microbial communities are associated with changes in lipid metabolism, glucose homeostasis, intestinal barrier functions, and chronic inflammation, all of which can lead to metabolic disorders. Therefore, the gut microbiome may represent a novel therapeutic target for obesity, type 2 diabetes, and nonalcoholic fatty liver disease. This review discusses how gut microbes and their products affect metabolic diseases and outlines potential treatment approaches via manipulation of the gut microbiome. Increasing our understanding of the interactions between the gut microbiome and host metabolism may help restore the healthy symbiotic relationship between them.Entities:
Keywords: inflammation; lipid; metabolic disease; microbiome; obesity
Mesh:
Year: 2022 PMID: 35511325 DOI: 10.1007/s12275-022-2087-y
Source DB: PubMed Journal: J Microbiol ISSN: 1225-8873 Impact factor: 3.422